Cue Biopharma (CUE) Non-Current Assets (2017 - 2026)

Cue Biopharma has disclosed Non-Current Assets across 10 years of filings, most recently posting $4.1 million for Q2 2026.

• In Q2 2026, Non-Current Assets fell 58.59% year-over-year to $4.1 million; the TTM figure through Jun 2026 stood at $25.0 million (down 18.81% YoY), while the FY2025 annual figure was $5.2 million, down 25.86% from the prior year.
• Non-Current Assets came in at $4.1 million for Q2 2026 at Cue Biopharma, down from $5.2 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $15.7 million in Q2 2022 to a low of $4.1 million in Q2 2026.
• Average Non-Current Assets over 5 years is $10.0 million, with a median of $9.9 million recorded in 2025.
• Year-over-year, Non-Current Assets jumped 69.37% in 2022 and plunged 58.59% in 2026.
• Over 5 years, Non-Current Assets stood at $14.1 million in 2022, then slipped by 28.52% to $10.1 million in 2023, then sank by 30.0% to $7.1 million in 2024, then declined by 25.86% to $5.2 million in 2025, then retreated by 21.9% to $4.1 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $4.1 million in Q2 2026, $5.2 million in Q4 2025, and $5.8 million in Q3 2025.